What is ergocalciferol used for
Pro Research Analysisby 
Searched over 200M research papers
Uses of Ergocalciferol: A Comprehensive Overview
Ergocalciferol in Chronic Kidney Disease (CKD)
Treatment of CKD-Mineral and Bone Disorders
Ergocalciferol, also known as vitamin D2, is commonly used to manage mineral and bone disorders in patients with chronic kidney disease (CKD) stages 3 to 5. Research indicates that ergocalciferol effectively increases 25-hydroxyvitamin D levels significantly more than calcitriol, another form of vitamin D, without significant differences in maintaining serum calcium, phosphorus, and parathyroid hormone levels . Additionally, ergocalciferol has been shown to improve endothelial function in mild uraemia, suggesting potential cardiovascular benefits in CKD patients .
Secondary Hyperparathyroidism
In patients with CKD stages 3 and 4, ergocalciferol is used to treat secondary hyperparathyroidism (SHPT). Although it increases serum 25-hydroxyvitamin D levels, it is less effective than paricalcitol, a vitamin D receptor activator, in reducing parathyroid hormone levels . This indicates that while ergocalciferol is beneficial for vitamin D repletion, alternative treatments may be more effective for SHPT management.
Ergocalciferol in Cystic Fibrosis
Vitamin D Deficiency Correction
Ergocalciferol is also used to correct vitamin D deficiency in children and young adults with cystic fibrosis (CF). A high-dose regimen of 700,000 IU over 14 days has been shown to effectively achieve therapeutic levels of 25-hydroxyvitamin D in 94% of participants without causing toxicity . This suggests that ergocalciferol is a safe and effective option for rapid vitamin D repletion in CF patients.
Ergocalciferol in Hemodialysis Patients
Erythropoiesis and Biochemical Outcomes
In hemodialysis patients with vitamin D deficiency, ergocalciferol supplementation significantly increases serum 25-hydroxyvitamin D levels. However, it does not significantly affect epoetin utilization, serum calcium, phosphorus, parathyroid hormone levels, or hospitalization rates . This indicates that while ergocalciferol is effective for vitamin D repletion, it may not influence other clinical outcomes in hemodialysis patients.
Ergocalciferol in Type 1 Diabetes
Anti-inflammatory and Immunomodulatory Effects
Ergocalciferol has been studied for its potential benefits in youth with newly diagnosed type 1 diabetes (T1D). Supplementation has been shown to reduce serum tumor necrosis factor-alpha (TNF-α) levels and slow the increase in glycated hemoglobin A1c (HbA1c) and insulin dose-adjusted A1c (IDAA1c), suggesting a protective effect on residual β-cell function and partial clinical remission . This highlights ergocalciferol's potential role in modulating inflammation and improving clinical outcomes in T1D.
Ergocalciferol in Cancer Treatment
Induction of Apoptosis in Leukemia Cells
Ergocalciferol has demonstrated anticancer properties by inducing apoptosis in human leukemia cells. It promotes DNA fragmentation, mitochondrial dysfunction, reactive oxygen species (ROS) generation, and caspase activation, leading to cell death . These findings suggest that ergocalciferol could be explored as a chemopreventive agent in cancer therapy.
Conclusion
Ergocalciferol is a versatile form of vitamin D2 with applications across various medical conditions. It is effective in managing CKD-related mineral and bone disorders, correcting vitamin D deficiency in cystic fibrosis, and potentially offering anti-inflammatory benefits in type 1 diabetes. Additionally, its role in inducing apoptosis in leukemia cells opens avenues for cancer treatment. While ergocalciferol is beneficial for vitamin D repletion, its efficacy in other clinical outcomes may vary, necessitating further research to optimize its therapeutic use.
Sources and full results
Most relevant research papers on this topic